NaV1.5 regulation fine-tuning as a therapy for cardiac Conduction and Arrhythmic diseases at Risk of suddEn Deathbroad
NaV1.5-CARED · Horizon Europe grant · 2023-10-01–2028-09-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-PATHFINDERCHALLENGES-01 · scheme HORIZON-EIC · topic HORIZON-EIC-2022-PATHFINDERCHALLENGES-01-03. CORDIS record →
Objective
The voltage-gated sodium channel (Na-channel; NaV1.5) is a central component of cardiac electrogenesis. Its dysfunction can lead to ventricular fibrillation and sudden cardiac death. While NaV1.5 represents a highly relevant therapeutic target for prevention of life-threatening cardiac arrhythmias, therapies that target the expression or function of this channel are non-existent. Such a therapy would provide for the first time an alternative for the invasive and costly cardioverter defibrillator or pacemaker therapies currently used. NaV1.5-CARED consortium proposes to capitalize on their largest worldwide cohorts of patients with inherited cardiac electrical and conduction defects to uncover regulatory regions and proteins that modulate NaV1.5 expression and function with the goal to develop and validate innovative therapies to restore the function of NaV1.5. We have three objectives: 1) predict the risk of (fatal) arrhythmia and conduction defect at the individual level by developing personalized polygenic risk score (PRS), 2) characterize the molecular mechanism associating regulatory DNA regions and genes with the cardiac diseases to uncover new therapeutic targets, 3) and develop new candidates for therapeutic intervention able to restore Nav1.5 loss of function. After databases harmonization, we will conduct whole genome genetic studies to identify variants associated with ventricular arrhythmia and conduction defects and generate PRS relevant to stratify the risk of arrhythmia and degree of conduction defect. Genetic studies will also be used to identify new therapeutic that will be evaluated in dedicated and high-throughput human cardiomyocytes derived induced pluripotent cell models.
Beneficiaries (8)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | FR | coordinator | €1,807,062 | |
| STICHTING AMSTERDAM UMC | NL | participant | €999,854 | |
| PACINGCURE B.V. | NL | participant | €937,500 | Yes |
| MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC) | DE | participant | €383,750 | |
| FAKULTNI NEMOCNICE U SV ANNY V BRNE | CZ | participant | €314,801 | |
| SMARTOX | FR | participant | €271,125 | |
| CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES | FR | participant | €178,164 | |
| NANTES UNIVERSITE | FR | thirdParty | €0 |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.